In PDA, recent studies demonstrate that the dimer of Integrins αVβ6 (ITGAV / ITGB6) is overexpressed in most tumors (with overexpression being retained in the corresponding metastases) and is a feasible target for novel therapeutic approaches [7, 8]. Here, ITGAV is linked to Patent ductus arteriosus.